RenovoRx Inc

RNXT

Company Profile

  • Business description

    RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.

  • Contact

    2570 West El Camino Real
    Suite 320
    Mountain ViewCA94040
    USA

    T: +1 650 284-4433

    https://www.renovorx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    10

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,323.47327.17-0.73%
FTSE 1008,941.1234.54-0.38%
HKSE24,139.57111.200.46%
NASDAQ20,621.569.11-0.04%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,259.3221.14-0.34%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers